IGBA Criticizes Export Restrictions
Supply Disruptions Are Counter-Productive During Coronavirus Crisis
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
You may also be interested in...
Indian Industry Gets HCQ, Paracetamol Exports Rolling
Indian manufacturers hope increased production of hydroxychloroquine and paracetamol, along with emergence of reliable COVID-19 therapies, will lead to export restrictions on these two medicines being removed soon. Meanwhile, they are fulfilling orders routed through the government.
Customs And Trade Bodies Join Forces To Minimize Disruption
The World Customs Organization and World Trade Organization have pledged to work together to break down trade barriers for essential supplies in the fight against the coronavirus pandemic.
India Lifts Export Restrictions
India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.